BRIGHTSTAR: Local Consolidative Therapy with Brigatinib in Tyrosine Kinase Inhibitor-Naïve ALK-Rearranged Metastatic NSCLC
Expert oncologist Yasir Elamin, MD, shares data from the BRIGHTSTAR trial and considers how it may inform real-world use of brigatinib in patient with ALK-rearranged metastatic non–small cell lung cancer.
Yasir Elamin Local Consolidative Therapy Tyrosine Kinase Inhibitor Na Rearranged Metastatic Non Small Cell Lung Cancer Lung Cancer
Source: onclive.com